TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Rating of “Hold” from Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has earned an average rating of “Hold” from the thirteen research firms that are presently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $134.00.

Several brokerages have commented on TMDX. Canaccord Genuity Group cut their price target on shares of TransMedics Group from $152.00 to $124.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Piper Sandler reduced their price objective on shares of TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Oppenheimer downgraded shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 6th. JPMorgan Chase & Co. increased their price objective on shares of TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Finally, Wall Street Zen downgraded shares of TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th.

TransMedics Group Trading Up 0.5%

Shares of NASDAQ:TMDX opened at $67.53 on Tuesday. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. The company’s fifty day simple moving average is $92.00 and its 200 day simple moving average is $118.27. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of 15.35 and a beta of 1.92.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The company had revenue of $173.93 million for the quarter, compared to analyst estimates of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The company’s revenue was up 21.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.70 earnings per share. As a group, research analysts forecast that TransMedics Group will post 1.98 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In other news, Director Stephanie Lovell sold 1,193 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $149.62, for a total transaction of $178,496.66. Following the completion of the transaction, the director directly owned 2,866 shares in the company, valued at $428,810.92. This represents a 29.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Gerardo Hernandez sold 7,236 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $147.21, for a total transaction of $1,065,211.56. Following the transaction, the chief financial officer owned 14,689 shares of the company’s stock, valued at approximately $2,162,367.69. This represents a 33.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 12,000 shares of company stock worth $1,768,002 in the last three months. Insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of large investors have recently modified their holdings of TMDX. Goldman Sachs Group Inc. raised its holdings in shares of TransMedics Group by 50.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after purchasing an additional 322,353 shares during the period. Two Sigma Investments LP raised its holdings in shares of TransMedics Group by 54.2% in the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after purchasing an additional 223,409 shares during the period. Wellington Management Group LLP raised its holdings in shares of TransMedics Group by 100.5% in the 4th quarter. Wellington Management Group LLP now owns 433,321 shares of the company’s stock valued at $52,713,000 after purchasing an additional 217,180 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of TransMedics Group by 43.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock valued at $69,338,000 after purchasing an additional 171,810 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of TransMedics Group by 11.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock valued at $119,997,000 after purchasing an additional 113,817 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.